N-trifluoromethyl-p-toluidine | 660-32-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-trifluoromethyl-p-toluidine
• 英文别名: N-Trifluormethyl-p-toluidin；4-methyl-N-(trifluoromethyl)aniline
• CAS: 660-32-2
• 化学式: C₈H₈F₃N
• 分子量: 175.153
• InChiKey: PPQBGGLGUHCGRC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-4-methylphenyl isocyanodichloride 在 氢氟酸 作用下， 生成 N-trifluoromethyl-p-toluidine
  参考文献：
  名称：

  Petrow; Neimyschewa, Zhurnal Obshchei Khimii, 1959, vol. 29, p. 2169,2172;engl.Ausg.S.2135,2138

  摘要：

  DOI：

文献信息

• [EN] COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF<br/>[FR] COMPOSÉS DESTINÉS À L'INHIBITION DE TNIK ET UTILISATIONS MÉDICALES ASSOCIÉES
  申请人：KOREA RES INST CHEMICAL TECH

  公开号：WO2019156439A1

  公开（公告）日：2019-08-15

  The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.

  本公开提供了具有抑制TNIK活性的化合物，其具有特定化学结构或其药用可接受盐。本公开还提供了包含该化合物或其药用可接受盐的组合物。本公开还提供了该化合物、其盐或包含该化合物或其药用可接受盐的组合物的医疗用途，用于治疗或预防癌症。本公开还提供了一种治疗或预防癌症的方法，包括向需要此类治疗或预防的受试者施用该化合物、其盐或包含该化合物或其盐的组合物。
• Electrophotographic member
  申请人：HITACHI CHEMICAL CO., LTD.

  公开号：EP0475676A1

  公开（公告）日：1992-03-18

  Disclosed is an electrophotographic member containing as a charge transport material a fluorine-containing N,N,N′,N′-tetraarylbenzidine derivative which is remarkably excellent in solubility in an organic solvent and/or a binder such as polycarbonate resin, etc., can show very excellent electrophotographic properties such as high sensitivity, low residual potential and high durability. Further, a fluorine-containing N,N,N′,N′-tetraarylbenzidine derivative usable as a charge transport material, and a process for producing the same are disclosed. Furthermore, a fluorine-containing diarylamine usable for producing the fluorine-containing N,N,N′,N′-tetraarylbenzidine derivative, and a process for producing the same are disclosed.

  本发明公开了一种含有含氟 N，N，N′，N′-四芳基联苯胺衍生物作为电荷传输材料的电致发光构件，该衍生物在有机溶剂和/或聚碳酸酯树脂等粘合剂中的溶解性极佳，可显示出非常优异的电致发光性能，例如高灵敏度、低残留电位和高耐久性。此外，还公开了一种可用作电荷传输材料的含氟 N,N,N′,N′-四芳基联苯胺衍生物及其生产工艺。此外，还公开了一种可用于生产含氟 N,N,N′,N′-四芳基联苯胺衍生物的含氟二芳基胺及其生产工艺。
• COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：Hyundai Pharm Co., Ltd.

  公开号：EP3121167A1

  公开（公告）日：2017-01-25

  The present invention relates to a compound inhibiting CDK5-mediated PPARG phosphorylation and a pharmaceutical composition for treating PPARG-related diseases containing the same as an active ingredient. A compound represented by formula 1 or an optical isomer thereof according to the present invention binds to PPARG at a high affinity level, but does not act as an agonist, thereby inducing no gene transcription; blocks CDK5, which is a cause of PPARG phosphorylation, thereby causing no side effects of existing anti-diabetics; can be formulated into drugs due to improved pharmacological properties thereof; and can be favorably used as a pharmaceutical composition for treating PPARG-related diseases due to an excellent treatment effect on PPARG-related diseases.

  本发明涉及一种抑制 CDK5 介导的 PPARG 磷酸化的化合物，以及一种治疗 PPARG 相关疾病的药物组合物，其活性成分含有该化合物。根据本发明的由式 1 或其光学异构体代表的化合物能以高亲和力与 PPARG 结合，但不作为激动剂，因此不会诱导基因转录；能阻断导致 PPARG 磷酸化的 CDK5，因此不会引起现有抗糖尿病药物的副作用；由于其药理性质的改善，可配制成药物；由于对 PPARG 相关疾病有很好的治疗效果，可作为治疗 PPARG 相关疾病的药物组合物。
• NOVEL BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE OF SAME
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP3348547A1

  公开（公告）日：2018-07-18

  The present invention provides a medicament for treating a disease involving Nav 1.7 such as neuropathic pain, nociceptive pain, inflammatory pain, small-fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, dysuria, and multiple sclerosis, which comprises a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1a, R1d, R1c and R1d are hydrogen, halogen, cyano, C1-4 alkyl, C1-4 alkoxy, or the like, provided that at least one of R1a, R1b, R1c and R1d is C6-10 aryl, C6-10 aryloxy, or the like, R2 and R3 are hydrogen, C1-6 alkyl, C3-10 cycloalkyl, or the like, R4 is hydrogen, C1-6 alkyl, C3-7 cycloalkyl, or the like, m is 1, 2 or 3, L is CR7R8, and R7 and R8 are hydrogen, hydroxyl, C1-4 alkyl, C1-4 alkoxy, or the like.

  本发明提供了一种用于治疗涉及 Nav 1.7 的疾病（如神经性疼痛、痛觉过敏、炎症性疼痛、小纤维神经病、红斑性疼痛、阵发性极度疼痛症、排尿困难和多发性硬化症）的药物，它包括式（I）化合物： 或其药学上可接受的盐，其中 R1a、R1d、R1c 和 R1d 是氢、卤素、氰基、C1-4 烷基、C1-4 烷氧基或类似物，条件是 R1a、R1b、R1c 和 R1d 中至少有一个是 C6-10 芳基、C6-10 芳氧基或类似物、R2和R3是氢、C1-6烷基、C3-10环烷基或类似物，R4是氢、C1-6烷基、C3-7环烷基或类似物，m是1、2或3，L是CR7R8，R7和R8是氢、羟基、C1-4烷基、C1-4烷氧基或类似物。
• COPOLYMER, AND LIQUID CRYSTAL ALIGNMENT LAYER COMPRISING HARDENED PRODUCT THEREOF
  申请人：DIC Corporation

  公开号：EP2727947B1

  公开（公告）日：2017-03-15